The 16th JFCR-ISCC

January 25-26, 2012
Miraikan (National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan

The 16th JFCR-ISCC: New Antitumor Agents under Development in the US, Europe and Japan

The 16th Symposium Program Committee

Hiroyuki Seimiya (Program Committee Chairman, Cancer Chemotherapy Ctr.)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd.)
Naoya Fujita (Cancer Chemotherapy Ctr.)
Kiyohiko Hatake (Cancer Chemotherapy Ctr.)
Manabu Kawada (Inst. Microbial Chem.)
Atsushi Ohtsu (National Cancer Ctr. Hospital East)
Isamu Okamoto (Kinki Univ.)
Seiji Yano (Kanazawa Univ.)

January 25

11:00-13:00

Poster mounting

12:00-12:30

Committee Meeting

Opening remark

13:00-13:10

Mitsuaki Yoshida (Cancer Chemotherapy Center)

Opening remark

INew concepts for combination therapy and upcoming drugs

Chairpersons: Yves G. Pommier (National Cancer Institute)
Takao Yamori (Cancer Chemotherapy Center, JFCR)

13:10-13:45

Steven Grant (Virginia Commonwealth University)

New strategies for combining targeted therapies in hematologic malignancies

13:45-14:10

Takayuki Yoshino (National Cancer Center Hospital East)

TAS-102, a Novel Nucleoside Antitumor Agent for Metastatic Colorectal Cancer

14:10-14:20

Discussion

14:20-14:40

Coffee break

II New wave in antibody therapy

Chairpersons:Tomoki Naoe (Nagoya University)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd.)

14:40-15:10

Wenru Song (Millennium)

Brentuximab Vedotin (Adcetris), an Antibody–Drug Conjugate for the Treatment of CD30-Positive Malignancies

15:10-15:40

Mark Sliwkowski (Genentech)

Multiple Approaches to Targeting HER/ErbB Receptors in Solid Tumors

15:40-15:50

Discussion

Poster Session

15:50-16:50

Junji Matsui (Eisai Co., Ltd)

Lenvatinib (E7080), a selective VEGFR/FGFR tyrosine kinase inhibitor (TKI) as a melanoma therapy for BRAF wild type melanoma and combination therapy with vemurafenib for V600E BRAF melanoma

 

Hiroyuki Arai (GlaxoSmithKline K.K.)

Epidemiology of breast cancer in Japan and pharmacological profile of lapatinib

 

Tadaaki Yamada (Kanazawa University)

Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer

 

Hiroshi Tanaka (Chugai Pharmaceutical Co., Ltd.)

The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations

 

Makoto Kawatani (RIKEN)

Identification of novel tubulin polymerization inhibitors by proteomic profiling

 

Keiichiro Okuhira (National Institute of Health Sciences)

Degradation of estrogen receptor induced by a small hybrid molecule SNIPER(ER)

 

Satoshi Takagi (Cancer Chemotherapy Center)

Suppression of tumor metastasis by anti-Aggrus/podoplanin neutralizing antibodies

 

Osamu Kondoh (Chugai Pharmaceutical Co., Ltd.)

Targeting microtubule-associated protein 4 with novel small molecule CH4938056 confers antitumor activity under quasi in vivo conditions and in xenograft models

 

Haruyasu Murakami (Shizuoka Cancer Center)

The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase 1 trial in Japanese patients with metastatic solid tumors

 

Takahiro Ishiguro (Chugai Pharmaceutical Co., Ltd.)

Anti-Glypican3 antibody for treatment of human liver cancer

 

Takeharu Sakamoto (The Univesity of Tokyo)

Mint3 is a new molecular target for metastasis suppression

 

Ryoji Yao (Cancer Institute, JFCR)

Disruption of TACC3 leads to in vivo tumor regression by targeting spindle assembly.

16:50-18:30

Mixer

January 26

III Oncogene addiction targets (1)

Chairpersons: Mark Sliwkowski (Genentech)
Saburo Sone (JA Kochi Hospital)

9:00-9:35

Brian Schwartz (Arqule Inc)

Discovery and Development of Tivantinib, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Solid Tumors.

9:35-10:00

Hiroshi Sakamoto (Chugai Pharmaceutical Co., Ltd.)

CH5424802: A selective ALK inhibitor

10:00-10:10

Discussion

10:10-10:30

Coffee break

Poster Discussion Session

Chairperson: Yoshikazu Sugimoto (Keio University)

10:30-11:45

Mentor: Dr. Bruce Chabner

Poster #: P1-P4


Mentor: Dr. Jaap Verweij

Poster #: P5-P8


Mentor: Dr. Yves G. Pommier

Poster #: P9-P12

12:00-12:30

Lunch

12:30-15:15

Poster removal

Special Lecture

Chairperson: Tetsuichiro Muto (JFCR)

12:45-13:35

Hideyuki Saya (Keio University)

Regulation and therapeutic targeting of cancer stem cells

Meet-the-Expert Seminars (1)

Chairperson: Ryuzo Ueda (Nagoya City University)

13:35-14:15

Bruce A. Chabner (MGH Cancer Center)

Epigenetics, the next frontier for cancer drug discovery

Meet-the-Expert Seminars (2)

Chairperson: Atsushi Ohtsu (National Cancer Center Hospital East)

14:15-14:55

Jaap Verweij (Erasmus University Medical Center)

Challenges and pitfalls in drug development. A personal experience

14:55-15:15

Coffee break

IV Oncogene addiction targets (2)

Chairpersons: Brian Schwartz (ArQule Inc.)
Yoshiro Niitsu (Sapporo Medical University)

15:15-15:45

Kathleen Schostack (Roche)

Development of vemurafenib: from target to personalized medicine and beyond

15:45-16:15

Erkut Bahceci (Astellas)

AC220 (quizartinib) for FLT3-ITD Positive Acute Myeloid Leukemia

16:15-16:25

Discussion

V Non-oncogene addiction targets

Chairpersons: Steven Grant (Virginia Commonwealth University)
Kiyohiko Hatake (Cancer Chemotherapy Center, JFCR)

16:25-17:00

Yves G. Pommier (National Cancer Institute)

Chk2: Targeting the DNA damage and cell cycle checkpoint

17:00-17:25

Toshihiko Doi (National Cancer Center Hospital East)

Targeting polo-like kinase 1 for cancer therapy

17:25-17:35

Discussion

Closing remark

17:35-17:45

Bruce A. Chabner (MGH)

Closing Remark

For further information

please contact:
Ritsuko Mihara
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-8-31, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3570-0661 FAX: 81-3-3570-0484
Mail: ritsuko.mihara@jfcr.or.jp

Page TOP